Alpha Tau Medical (DRTS) Cash & Equivalents (2020 - 2026)

Alpha Tau Medical has disclosed Cash & Equivalents across 7 years of filings, most recently posting $4.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $4.6 million, down 7.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 million (down 7.63% YoY), and the FY2025 annual result was $12.2 million, down 11.09% from the prior year.
• Cash & Equivalents came in at $4.6 million for Q1 2026 at Alpha Tau Medical, down from $12.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $98.9 million in Q1 2022 to a low of $82000.0 in Q3 2023.
• The 5-year median for Cash & Equivalents is $5.8 million (2022), against an average of $12.0 million.
• Across the five-year window, Cash & Equivalents tumbled 99.09% in 2023 and surged 6639.02% in 2024, its largest moves.
• Alpha Tau Medical's Cash & Equivalents stood at $5.8 million in 2022, then jumped by 116.88% to $12.7 million in 2023, then rose by 8.43% to $13.7 million in 2024, then slipped by 11.09% to $12.2 million in 2025, then tumbled by 62.01% to $4.6 million in 2026.
• The last three Cash & Equivalents figures came in at $4.6 million (Q1 2026), $12.2 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.